Levetiracetam Aristo

Levetiracetam, the active ingredient in Levetiracetam Aristo, is an antiepileptic presented as an oral dosage form for oral use. It is employed to control various seizure types in patients with epilepsy. Levetiracetam Aristo is supplied as a prescription‑only product and is not classified as a controlled substance.

GNH USA supplies Levetiracetam Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that acts on neuronal excitability to reduce seizure activity.

- Partial‑onset seizures: helps achieve seizure control and reduces frequency of focal seizures. - Generalized tonic‑clonic seizures: contributes to preventing convulsive episodes across the brain. - Myoclonic seizures: assists in decreasing rapid, involuntary muscle jerks associated with this seizure type.

Levetiracetam may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or lacking energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate head pain. - Irritability: mood changes or increased agitation. - Nausea: upset stomach or feeling of needing to vomit.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive ideation or self‑harm. - Depression: new or worsening mood disorder. - Allergic reactions: rash, swelling, or anaphylaxis. - Blood dyscrasias: abnormal blood counts or leukopenia. - Respiratory depression: marked slowing of breathing, especially with CNS depressants.

When prescribing Levetiracetam, clinicians should consider several safety aspects.

- Renal impairment: adjust dose or monitor levels in patients with reduced kidney function. - Hepatic impairment: use caution and consider dose modification for liver disease. - Psychiatric history: monitor for mood changes, depression, or suicidal ideation. - Concomitant CNS depressants: watch for additive sedation or respiratory effects. - Pregnancy: safety data are limited; evaluate risk‑benefit before use. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam levels. - Phenytoin: may reduce seizure control when combined. - Phenobarbital: can decrease levetiracetam exposure. - Rifampin: strong inducer that may diminish therapeutic effect. - Oral contraceptives: reduced efficacy, increasing risk of unintended pregnancy.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam concentrations. - Alcohol: additive central nervous system depression. - Other antiepileptics: monitor for cumulative sedation. - Sedatives (e.g., benzodiazepines): watch for enhanced drowsiness. - Antidepressants: potential for mood alterations.